GSK director buys 3,334 shares at £22.19

GSK plc reported a share purchase by one of its board members.

Rhea-AI Filing Summary

GSK plc reported a share purchase by one of its board members. Independent Non-Executive Director Wendy Becker bought 3,334 ordinary shares of GSK at a price of £22.1926 per share. The transaction took place on 20 February 2026 on the London Stock Exchange.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this 6-K?

GSK disclosed that Independent Non-Executive Director Wendy Becker purchased 3,334 ordinary shares. The shares were bought on the London Stock Exchange at £22.1926 per share, indicating a director increasing her personal holding in the company’s stock.

How many GSK (GSK) shares did Wendy Becker buy and at what price?

Wendy Becker bought 3,334 GSK ordinary shares at £22.1926 each. This single transaction was executed on the London Stock Exchange and was formally reported as a transaction by a person discharging managerial responsibilities (PDMR).

When and where was the GSK (GSK) director share purchase executed?

The director share purchase was executed on 20 February 2026 on the London Stock Exchange (XLON). The filing records this as a single transaction in GSK ordinary shares of 31¼ pence each, identified by ISIN GB00BN7SWP63.

Who at GSK (GSK) is reported as the person discharging managerial responsibilities?

The person discharging managerial responsibilities is Wendy Becker, an Independent Non-Executive Director of GSK plc. Her role and status as a PDMR require disclosure of transactions in GSK shares under applicable market abuse and transparency regulations.

What type of financial instrument did the GSK (GSK) director acquire?

The director acquired GSK plc ordinary shares of 31¼ pence each. These ordinary shares are identified in the filing by ISIN GB00BN7SWP63 and were purchased on the London Stock Exchange as a single reportable transaction.

Is the GSK (GSK) director’s transaction reported as a single or aggregated trade?

The transaction is reported as a single trade. Aggregated information is marked as not applicable in the disclosure, confirming that the 3,334 GSK ordinary shares were purchased in one transaction at a price of £22.1926 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 11:12 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Wendy Becker
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ​ ISIN: GB00BN7SWP63 ​
b)	Nature of the transaction	Purchase of 3,334 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.1926	3,334
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-20
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 20, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc